Restricting dietary fructose significantly reduces serum glucoselysine (GL), a fructose-specific glycation product, in two independent human studies. In a case-control comparison, adults with hereditary fructose intolerance following strict fructose-free diets had GL levels of 35.1 nmol/L versus 45.8 nmol/L in matched healthy controls — a 23% difference. In a double-blind randomized controlled trial of 35 overweight adults with hepatic steatosis, fructose restriction drove GL from 38.8 to 31.2 nmol/L, an absolute reduction of 8.0 nmol/L (95% CI: −12.0 to −4.5). Crucially, GL levels did not normalize to zero after fructose elimination, pointing to endogenous fructose production as a residual source.
Glucation products more broadly — think advanced glycation end-products (AGEs) from glucose — are established players in vascular aging, kidney disease, and diabetic complications. GL is conceptually similar but fructose-specific, and fructose glycates proteins roughly tenfold faster than glucose, making it mechanistically plausible as a cardiometabolic culprit beyond simple caloric contribution. This study is noteworthy for establishing a validated serum assay and providing the first controlled dietary evidence in humans that exogenous fructose drives GL formation. Limitations include small samples (n=15 and n=35), the hepatic steatosis population limiting generalizability, and the absence of hard cardiovascular outcomes — GL remains a candidate biomarker, not yet a proven mediator. Nonetheless, this is a meaningful proof-of-concept: reducing added fructose intake measurably alters a mechanistically relevant glycation pathway.